Welcome to our dedicated page for Entero Therapeutics SEC filings (Ticker: ENTO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking a clinical-stage biotech like Entero Therapeutics Inc. (ENTO) often means combing through dense scientific disclosures just to confirm whether latiglutenase advanced to Phase 3 or how fast cash burns. If you have ever typed “Entero Therapeutics SEC filings explained simply” or wondered where the next data read-out is buried, this page solves that problem.
Stock Titan’s AI digests every document the instant it hits EDGAR, turning a 300-page 10-K into plain-language insight. Need the “Entero Therapeutics annual report 10-K simplified” for risk factors or pipeline timelines? Curious about “Entero Therapeutics quarterly earnings report 10-Q filing” cash trends? Our platform answers those natural questions and more, including “understanding Entero Therapeutics SEC documents with AI” in minutes, not hours. Real-time alerts surface “Entero Therapeutics Form 4 insider transactions real-time” so you can monitor “Entero Therapeutics executive stock transactions Form 4” before the market reacts.
- 10-K & 10-Q: Trial costs, cash runway, and segment reporting, paired with “Entero Therapeutics earnings report filing analysis.”
- 8-K: Immediate updates on clinical data or licensing deals—“Entero Therapeutics 8-K material events explained.”
- Form 4: “Entero Therapeutics insider trading Form 4 transactions” flagged the moment executives buy or sell.
- Proxy (DEF 14A): “Entero Therapeutics proxy statement executive compensation” broken down so option packages are clear.
With comprehensive coverage, AI-powered summaries, and expert context, you’ll never miss a development that could move ENTO’s valuation. Discover, analyze, and act—without wading through biotech jargon.
Document scope and corporate actions: This S-1/A incorporates the company’s 2024 Annual Report on Form 10-K and 10-Qs for March 31, 2025 and June 30, 2025 and states that all historical share and per-share figures reflect a 1-for-3 reverse stock split effective August 18, 2025. The filing lists authorized capital of 100,000,000 common shares and 10,000,000 preferred shares.
Intellectual property and patents: The filing references multiple patent families, including European and U.S. patents for a Yarrowia lipolytica lipase (European expiry June 15, 2026; U.S. expirations Sept 11, 2028 and July 17, 2026) and issued U.S. patents for inflammatory-condition treatments expiring Sept 1, 2036 and patents directed to niclosamide use expiring March 31, 2040.
Other material items: The prospectus lists risks and cost items related to development, regulatory approval, manufacturing, commercialization, patent prosecution and personnel. It discloses selling-stockholder warrant holdings with a 4.9% beneficial ownership exercise limitation and includes signatures dated September 10, 2025.
FAQ
What is the current stock price of Entero Therapeutics (ENTO)?
What is the market cap of Entero Therapeutics (ENTO)?
